Who is sponsoring NCT06062524?

NCT06062524 is sponsored by Hangzhou Endonom Medtech Co., Ltd..

What drugs are being tested in NCT06062524?

Interventions in NCT06062524: Aorta Vascular Plug System.

What condition does NCT06062524 study?

NCT06062524 studies Aortic Dissection Aneurysm.

Is NCT06062524 still recruiting?

NCT06062524 is currently recruiting now. Last updated 22 May 2024.

Last reviewed 2024-05-22 · How we verify

NCT06062524

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Guo's False Lumen Embolization : The First in Man Study of WeFlow-EndoSeal Aorta Vascular Plug System

Recruiting now NA Last updated 22 May 2024

What this trial tests

NA trial testing Aorta Vascular Plug System in Aortic Dissection Aneurysm in 20 participants. Currently enrolling.

Timeline

24 October 2023

Primary endpoint
31 May 2026

31 May 2026

Quick facts

Lead sponsor	Hangzhou Endonom Medtech Co., Ltd.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	24 October 2023
Primary completion	31 May 2026
Estimated completion	31 May 2026
Sites	3 locations across China

Drugs / interventions tested

Aorta Vascular Plug System

Conditions studied

Aortic Dissection Aneurysm — all drugs for Aortic Dissection Aneurysm →

Sponsor

Hangzhou Endonom Medtech Co., Ltd.

Who can join

Adults 18 to 80, any sex, with Aortic Dissection Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, single-center, first in man study to evaluate the safety and efficacy of WeFlow-EndoSeal Aorta Vascular Plug System manufactured by Hangzhou Endonom Medtech Co., Ltd. for the dissecting aneurysm of descending thoracic aorta after aortic dissection repair.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

First in man: blocking the false lumen backflow of aortic dissection after thoracic endovascular aortic repair by an off-the-shelf EndoSeal™ system.
Ge Y, Zhang H, Guo W. · · 2024 · cited 4× · PMID 38427788 · DOI 10.1093/eurheartj/ehae117

Verify or expand the search:

Other Hangzhou Endonom Medtech Co., Ltd. trials

Trials by the same sponsor.

NCT07170332 — ZIPPER™ Stent-Graft Trial for Aortic Arch Dissection · NA · not yet recruiting
NCT06385379 — Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study) · NA · recruiting
NCT05872282 — Percutaneous Endovascular Arch Repair Trial (PEART) Study · NA · unknown
NCT05754541 — Guo's Endovascular Aortic Arch Replacement of Aortic Dissection by WeFlow-Tribranch Endoprothesis: a Multicenter Pilot S · NA · unknown
NCT05179967 — Safety and Efficacy Study of WeFlow-JAAA Stent Graft System for Complex Abdominal Aortic Aneurysm(GREAT Study) · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06062524 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hangzhou Endonom Medtech Co., Ltd.
Last refreshed: 22 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06062524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing